Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28211221 | 0.85 | CYP3A4 (0.42) | CYP3A4ALDH1A1TDP1TSHRTP53 | |
| SCHEMBL28754177 | 0.83 | PDE4A (0.44) | POLBCYP3A4ALDH1A1TDP1TSHR | |
| Hydrochloric Acid SCHEMBL28477097 | 0.82 | PDE4A (0.43) | POLBCYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL8778197 | 0.80 | ALDH1A1 (0.59) | POLBCYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL27904270 | 0.80 | ALDH1A1 (0.59) | POLBCYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL8954074 | 0.80 | DHFR (0.55) | CYP3A4ALDH1A1TDP1TSHRTP53 | |
| SCHEMBL19551144 | 0.79 | POLB (0.48) | POLBCYP3A4ALDH1A1TDP1TSHR | |
| SCHEMBL28853371 | 0.79 | CYP3A4 (0.39) | CYP3A4ALDH1A1TDP1TSHRTP53 | |
| SCHEMBL27838382 | 0.79 | HSD17B10 (0.50) | POLBCYP3A4ALDH1A1TDP1TP53 | |
| SCHEMBL9324203 | 0.78 | ALDH1A1 (0.46) | POLBCYP3A4ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716676-A | Application of polyimide in gas separation membrane | 浙江工业大学 | 2022-07-08 | — | — | CN | claimed |
| CN-111057260-A | Preparation method of black matte polyimide film | 株洲时代华鑫新材料技术有限公司 | 2020-04-24 | — | — | CN | claimed |
| US-20140113316-A1 | DEVICE, METHOD AND KIT FOR THE DETECTION OF DIFFERENT MARKERS IN DIFFERENT CELLULAR OR MOLECULAR TYPES AND THEIR QUANTIFICATIONS | MAZZEO ALESSANDRA (IT) | 2014-04-24 | — | — | US | claimed |
| JP-63091563-A | — | — | None | — | — | JP | disclosed |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | UNITED STATES GOVERNMENT | 2026-02-05 | — | — | US | disclosed |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORP (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4676530-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | Vakston, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12454565-B2 | PD-L1 analog fusion proteins for antigen specific immunotherapy and methods of use | AKSTON BIOSCIENCES CORPORATION (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250296978-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION | 2025-09-25 | — | — | US | disclosed |
| WO-2024186803-A2 | NUCLEOCAPSID ANTIGEN IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USE | AKSTON BIOSCIENCES CORPORATION (US) | 2024-09-12 | — | — | WO | disclosed |
| CN-1165299-A | Immunoassay for helicobacter pylori in fecal specimens | MERIDIAN DIAGNOSTICS INC (US) | 1997-11-19 | — | — | CN | disclosed |
| EP-0806667-A1 | Immunoassay for h. pylori in fecal specimens | MERIDIAN DIAGNOSTICS, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997017984-A1 | OLIGODENDROCYTE-SPECIFIC PROTEIN AND METHOD FOR TREATING DISEASE | RESEARCH GENETICS, INC. (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0407172-B1 | Aromatic polyimide separation membrane | MITSUBISHI CHEM IND (JP) | 1994-02-23 | — | — | EP | disclosed |
| WO-1994002648-A1 | GAP-FILLING NUCLEIC ACID AMPLIFICATION AND DETECTION | IMCLONE SYSTEMS INCORPORATED (US) | 1994-02-03 | — | — | WO | disclosed |
| US-5112941-A | A fluorinated membranes with high selectivity | MITSUBISHI KASEI CORPORATION (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0180564-B1 | IMMUNOGENIC COMPLEX, A METHOD FOR PRODUCING THE SAME, AND THE USE THEREOF AS AN IMMUNE STIMULANT, VACCINES AND REAGENTS | Morein, Bror (SE) | 1991-07-17 | — | — | EP | disclosed |
| EP-0407172-A1 | Aromatic polyimide separation membrane | MITSUBISHI KASEI CORPORATION (JP) | 1991-01-09 | — | — | EP | disclosed |
| JP-S6391563-A | EXAMINATION OF PROTEIN SPECIFIC ANTIGEN DERIVED FROM BACTERIA | NITSUSUI SEIYAKU KK | 1988-04-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035415-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | HM13, MYOF, SMN1; SMN2 | POLB 3069/4885CYP3A4 4818/4885ALDH1A1 4843/4885 |
| US-20260035433-A1 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | PDCD1LG2, CD274, PDCD1 | POLB 4281/4885CYP3A4 4698/4885ALDH1A1 3953/4885 |
| US-20260035414-A1 | HERV-K (HML-2) ENV ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | SMN1; SMN2, FUS, MORF4L1 | POLB 3105/4885CYP3A4 4844/4885ALDH1A1 4845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.